Metformin-associated lactic acidosis in patients with CKD with control of metformin dosage based on renal function: A case report and review of literature

Technical Summary: Metformin-Associated Lactic Acidosis in CKD with Dosage Control

Problem Statement
Metformin is the first-line therapy for type 2 diabetes mellitus due to its efficacy, low risk of hypoglycemia, and cardiovascular benefits. However, it carries a risk of metformin-associated lactic acidosis (MALA), a condition with a high mortality rate (25%–50%), particularly in patients with renal impairment. While metformin is contraindicated in severe renal failure (eGFR < 30 mL/min/1.73 m²), regulatory updates (e.g., FDA 2016) have permitted its use in moderate chronic kidney disease (CKD; eGFR 30–60 mL/min/1.73 m²) provided dosages are adjusted. Current literature suggests that with appropriate dose adjustments, metformin concentrations generally remain within the therapeutic range and lactate levels do not significantly increase. However, the clinical reality remains that MALA can still occur in CKD patients despite adherence to renal-function-based dosing guidelines, creating a diagnostic and therapeutic challenge.

Methodology
This study employs a dual approach:

1. Case Report: The authors present a detailed clinical case of a 50s male patient with Type 2 diabetes and Stage 3a CKD (baseline eGFR 49 mL/min/1.73 m²) who developed severe MALA while taking a renal-adjusted metformin dose (1500 mg/day). The patient presented with vomiting, acute kidney injury (AKI), severe lactic acidosis (lactate 14.5 mmol/L, pH 6.824), and hemodynamic instability (systolic BP dropping to 80 mmHg). Conservative management (hydration, bicarbonate infusion) failed to reverse the acidosis or shock. The patient was treated with Continuous Hemodiafiltration (CHDF) using a cellulose triacetate membrane.
2. Literature Review: The authors conducted a systematic review of existing literature to identify cases of MALA occurring in CKD patients despite appropriate metformin dose adjustments based on renal function. This review synthesized data from 11 previously reported cases (references 9–19) to analyze clinical characteristics, treatment modalities (Renal Replacement Therapy types), and outcomes.

Key Results

• Clinical Case Outcomes:
  • The patient's serum metformin concentration was confirmed to be in the toxic range (9.3 µg/mL).
  • Initiation of CHDF 11 hours after admission led to rapid clinical improvement. Within 4 hours, lactate levels began to decrease, and hemodynamic stability was restored (systolic BP rose to ~120 mmHg).
  • By 8 hours post-CHDF initiation, lactate dropped to 4.6 mmol/L and pH improved to 7.336.
  • CHDF was discontinued after 22 hours. Serum metformin levels became undetectable by day 5 and remained so on day 8.
  • Renal function gradually recovered (Creatinine decreased from 17.36 mg/dL to 2.63 mg/dL), and the patient was discharged on day 14 with continued improvement at the 2-month follow-up.
• Literature Review Findings:
  • The review identified 11 cases of MALA in CKD patients where metformin dosing was adjusted according to renal function.
  • 90.9% of these cases involved patients with CKD Stage G3a or G3b.
  • 81.8% of the reviewed cases required Renal Replacement Therapy (RRT).
  • Among those requiring RRT, Continuous Hemodiafiltration (CHDF) was utilized in three cases, and intermittent Hemodialysis (HD) in three others.
  • Most patients (90.9%) showed clinical improvement or survival, though the severity of acidosis (pH 6.50–7.2) and lactate levels (6.4–20.5 mmol/L) was profound.

Key Contributions

• Confirmation of Risk Despite Guidelines: The study provides empirical evidence that MALA can occur even when metformin dosing is strictly controlled based on renal function in CKD patients. This challenges the assumption that dose adjustment alone guarantees safety in moderate CKD.
• Identification of Precipitating Factors: The case highlights that acute kidney injury (potentially induced by dehydration, as suggested by the patient's history of working in hot conditions and vomiting) can precipitate MALA even in patients with previously stable renal function and appropriate dosing.
• Therapeutic Efficacy of CHDF: The paper demonstrates the utility of CHDF in managing MALA, particularly in hemodynamically unstable patients. Unlike intermittent hemodialysis, which may cause rapid solute shifts and hemodynamic instability, CHDF allowed for sustained correction of acid-base status and effective metformin elimination without compromising blood pressure.
• Clinical Guidance: The authors emphasize the necessity of discontinuing metformin during unexpected illnesses (adhering to "Sick Day Rules") to prevent AKI-induced MALA.

Significance and Claims
The authors claim that while metformin is generally considered safe for CKD patients with dose adjustments, clinicians must remain vigilant as MALA can still occur. The paper asserts that:

1. Early Recognition is Critical: Clinicians should suspect MALA in CKD patients presenting with severe metabolic acidosis, even if their dosing history appears compliant with guidelines.
2. CHDF as a Viable Option: For patients with MALA who are hemodynamically unstable, CHDF is a useful therapeutic option that stabilizes hemodynamics while facilitating the removal of metformin, which has a large volume of distribution and persists in erythrocytes.
3. Preventive Education: There is a critical need to educate both patients and medical staff to discontinue metformin immediately upon the onset of unexpected illness or dehydration to prevent the progression to severe MALA.

The study concludes that the management of MALA requires a low threshold for initiating extracorporeal treatments like CHDF, especially when standard supportive care fails or when hemodynamic instability is present.